Webinar will examine concerns around compounding anti-obesity medications

Surging demand for a new generation of highly effective anti-obesity medications is creating interest in compounded versions of these medications.

Endocrine Society experts will discuss the importance of prescribing FDA-approved medications to treat obesity during the Society’s Virtual Science Writers Conference on November 14.

What: The Virtual Science Writers Conference will examine:

• Rising demand for anti-obesity medications, including semaglutide and tirzepatide
• An FDA alert regarding the risk of dosing errors associated with compounded versions of these medications
• Strategies to navigate supply issues

Who:

• Caroline Apovian, M.D., F.A.C.P., of Brigham and Women's Hospital and Harvard Medical School in Boston, Mass.
• Maria Daniela Hurtado Andrade, M.D., Ph.D., of the Mayo Clinic in Jacksonville, Fla.

When: Thursday, Nov. 14 at 10 AM Eastern

Register to attend the virtual Science Writers Conference by emailing [email protected]. Registered reporters will receive log-in details.

Priority will be given to journalists seeking to register. The recording of this event will be made available on the Society’s YouTube channel for other audiences.

Eli Lilly provided support for this event.

About Endocrine Society

Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

The Society has more than 18,000 members, including scientists, physicians, educators, nurses, and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on X (formerly Twitter) at @TheEndoSociety and @EndoMedia.